338 filings
Page 9 of 17
8-K
6jd1t
27 Mar 18
Sorrento THERAPEUTICS Announces UNSECURED $120.5M Convertible note financing
12:00am
8-K
7gv2jaz20jg0f e1
19 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
lo9qu1
28 Feb 18
Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido™ (lidocaine topical system) 1.8% for PHN Pain
12:00am
8-K
txqmmsrl8prfzm xk
27 Feb 18
Material Impairments
12:00am
8-K
0rc1p
5 Feb 18
Regulation FD Disclosure
12:00am
8-K
di0czrg9
21 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
o09 puiavuc
18 Dec 17
Corporate Investor Presentation December 2017 V121617
12:00am
8-K
558hxs nb8
11 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
sw6h68v966k22noco5
14 Nov 17
Regulation FD Disclosure
12:00am
8-K
5n8y ydd3o0ivl4wts92
9 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
e3ry0g7 q651i9wf
6 Oct 17
Termination of a Material Definitive Agreement
12:00am
8-K
f0b8die
2 Oct 17
Departure of Directors or Certain Officers
12:00am
8-K
cqhi7ngklzvrromqo
12 Sep 17
Regulation FD Disclosure
12:00am
8-K
2tz4vkl5yfa
29 Aug 17
Regulation FD Disclosure
12:00am
8-K
edt03xr2 x78pb
21 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
jw9kl44nr b7
31 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
qpypzf qzuc
13 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
jjmqq78pvm cyredtv3
29 Jun 17
Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
12:00am
8-K
nm988suo7ska8odq
13 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
ixv7z
1 Jun 17
Other Events
12:00am